NYSE - CanSino Biologics Inc.

Сектор: Healthcare

График котировок CanSino Biologics Inc.

О компании

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.

подробнее
It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine. In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.

Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/BV 25.71
EV/EBITDA -11.14
Цена ао 38.36
P/S 465.91
EBITDA -0.4991

Все параметры ⇨

Оценка

Недооценка

Название Значение Оценка
P/S 465.91 1
P/BV 25.71 1
P/E 0
EV/EBITDA -11.14 10
Итого:

Эффективность

Название Значение Оценка
ROA, % -7.58 1
ROE, % -10.52 1
Итого:

Дивиденды

Название Значение Оценка
Div yield, % 0
DSI 0 0
Итого:

Долг

Название Значение Оценка
Долг/EBITDA 10
Итого:

Импульс роста

Название Значение Оценка
Рост прибыли, % 0 0
Рост цены акции, % 0 0
Рост дивидендов, % 0 0
Итого:

Основные владельцы

Институционалы Объем Доля, %
Capital Research and Management Company 35742862 14.44
Capital Guardian Trust Company 5459480 2.21
Capital International Inc 2455059 0.99
BlackRock Fund Advisors 1465006 0.59
Allianz Global Investors Asia Pacific Limited 517800 0.21
Matthews International Cap Mgmt LLc 376000 0.15
Fullgoal Fund Mgmt Co.,Ltd 353200 0.14
China International Fund Mgmt Co.,Ltd 317200 0.13
E Fund Mgmt Co.,Ltd 258400 0.1
MDO Management Company S.A. 200000 0.08
Carmignac Gestion 185600 0.08
DB Asset Management 151600 0.06
China Asset Mgmt Co.,Ltd 122400 0.05
Fullgoal Asset Management (HK) Ltd. 122200 0.05
BOCOM International Asset Management Ltd 110000 0.04
Franklin Templeton Sealand Fund Mgmt 95800 0.04
HFT Investment Mgmt Co., Ltd 81200 0.03
Krane Funds Advisors LLC 64600 0.03
Neuberger Berman Investment Advisers LLC 63000 0.03
Samsung Asset Management Co Ltd 20000 0.01
Renaissance Capital LLC 16390 0.01
Monega Kapitalanlagegesellschaft mbH 15400 0.01
Global X Management Company LLC 11620 0
Exchange Traded Concepts, LLC 9800 0
Rongtong Fund Mgmt Co.,Ltd 8000 0

Содержится в ETF

ETF Доля, % Доходность за год, % Дивиденды, %
FINEX CHINA UCITS ETF 0.107 128.53

Похожие компании